announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is operated by BioPharma Solutions (BPS), a business unit of Baxter that specializes in partnering with leading pharmaceutical and...
dievini Hopp BioTech holding GmbH & Co. KG is a holding company of SAP co-founder Dietmar Hopp with an investment focus on innovative biotechnology companies. dievini holds investments in ten companies – seven in Germany, two in Switzerland, one in Italy – almost all of which are developing...
Backed by over 90 years of Baxter innovation and expertise in parenterals – BPS is a premier CMO with a focus on injectable pharmaceutical manufacturing and collaborates with pharmaceutical companies to support commercialization for their molecules. We offer a broad portfolio of sterile fill finish pr...
Research & Development at Janssen Pharmaceutical Companies of Johnson & Johnson, a pharmaceutical company, where she was responsible for delivering the extensive pipeline on time and on budget. Dr. Loesberg also served in several executive roles at Bristol Myers Squibb, a global biopharmaceutical compa...
In the first half of 2022, Henlius has closed over multiple out-licensing deals for Henlius' four biosimilars on the market and other products in development. Through commercial collaborations with overseas pharmaceutical companies, t...
Baxter International Inc. recently announced an approximately $100-million expansion of its sterile fill/finish manufacturing facility located in Halle/Westfalen, Germany. This facility is...
UGA Biopharma proudly participated in Firmenlauf 2024, with 13 employees joining over 1,000 companies in Berlin for a spirited 5K run! UGA Biopharma ISO 9001 certified UGA Biopharma celebrates achieving ISO 9001:2015 certification, solidifying our commitment to top-tier quality in biopharma. Advancing...
17 Dec 2024 Efficacy and adverse event data from a phase II trial in Guillain-Barre syndrome released by Hansa Biopharma 05 Dec 2024 Hansa Biopharma completes enrolment in the phase III GOOD-IDES-02 trial for Anti-glomerular basement membrane disease in USA, Czech Republic, Germany, Netherlands...
In the first half of 2022, Henlius has closed over multiple out-licensing deals for Henlius' four biosimilars on the market and other products in development. Through commercial collaborations with overseas pharmaceutical companies, the company aimed to further promote the entry of self-developed produ...
GC Biopharma is one of the top-tier biopharmaceutical companies in South Korea with over 55 years of history and advanced technology. GC Biopharma provides premium Fill & Finish service to clinical and commercial customers for vaccines, recombinant and biosimilar pharmaceutical products. We have state...